The data showed Tecfidera (dimethyl fumarate), which is Biogen’s biggest selling product, improved time to relapse compared with some of its main competitors. But the data also showed an ...

Analysts forecast 'Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Rest of world' to reach $181.80 million. The estimate points to a change of +0.7% from the year-ago quarter.

When you first enter a new world, you can either spawn near a structure or find one while exploring any of the three dimensions. While finding some can be quite easy, others are extremely hard to ...

The team believes that the structure was in use until the 8th century BCE, the middle of the period when the Kings of Judah ruled. A scarab seal from the 8th century BCE uncovered during the ...

Biogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to its blockbuster Tecfidera that ... Vumerity (diroximel fumarate) for the treatment ...

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acschembio.4c00617. Fumarate ester clickable probe toolbox: gel-based ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Relapsing-remitting multiple sclerosis is a type of multiple sclerosis in which you experience relapses of the disease with periods of remission occurring in between. Relapsing-remitting multiple ...